Status:
COMPLETED
Efficacy of Lu 31-130 in Patients With Schizophrenia
Lead Sponsor:
H. Lundbeck A/S
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The main purpose with the study is to explore the efficacy and safety of Lu 31-130 in patients suffering from schizophrenia compared to a standard antipsychotic drug.
Detailed Description
Schizophrenia is a serious and disabling mental disorder that affects approximately 1% of the world's population. Antipsychotic drugs remain the cornerstone in the pharmacotherapy of schizophrenia. Ho...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- The subject has a primary diagnosis of schizophrenia
- The subject experiences clinically significant symptoms
- The subject is willing to be hospitalized during the initial period of the study
- The subject has normal serum values of parameters associated with liver function
Exclusion
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT00770744
Start Date
September 1 2008
End Date
November 1 2009
Last Update
November 8 2016
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
CZ001
České Budějovice, Czechia, 37087
2
CZ005
Litoměřice, Czechia, 41201
3
CZ004
Lnáře, Czechia, 38742
4
CZ002
Olomouc, Czechia, 77111